Measurable residual disease in the treatment of chronic lymphocytic leukemia

摘要

Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved sincechemoimmunotherapy and novel drugs became available for CLL treatment; therefore, moresensitive methods to evaluate residual CLL cells in patients are required. Measurableresidual disease (MRD) has been assessed in several clinical trials on CLL using flowcytometry, real-time quantitative PCR (RQ-PCR) with allele-specific oligonucleotide (ASO)primers, and high-throughput sequencing. MRD assessment is useful to predict the treatmentoutcomes in the context of chemotherapy and treatment with novel drugs such as venetoclax.In this review, we discuss major techniques for MRD assessment, data from relevantclinical trials, and the future of MRD assessment in CLL treatment.